Updates

The Australian Government Department of Health, Disability and Ageing has launched a new suite of self-service immunisation dashboards, providing healthcare professionals, policymakers and the community…

From 1 July 2026, all eligible Tasmanian infants can access free vaccination against meningococcal B disease through a new state-funded immunisation program.

From 1 July 2026, Australians eligible for pneumococcal vaccination can access a new pneumococcal conjugate vaccine through the National Immunisation Program (NIP), providing broader protection…

The Therapeutic Goods Administration (TGA) is reminding healthcare professionals to carefully check age eligibility before administering FluMist, following reports that the nasal spray influenza vaccine…

A new clinical practice review has highlighted that most vaccine-hesitant parents are not opposed to vaccination itself, but are primarily motivated by concerns about vaccine…

A new Australian study has found that a purpose-built decision-making tool may help travellers make more informed choices about Japanese encephalitis (JE) vaccination and increase…

Weekly report of year to date immunisation figures broken down by age groups and immunising provider types. Compares vaccination rates with the previous 3 years.

Capvaxive® will replace existing adult pneumococcal vaccines on the National Immunisation Program from 1 July 2026, simplifying the schedule and expanding protection against pneumococcal disease.

Eligible travellers visiting high-risk regions of New South Wales for outdoor recreational activities can continue to access free Japanese encephalitis virus (JEV) vaccination until 31…